A delegation from Yangtze River, the top pharmaceutical company in China, visited Siberia on business as part of the strategic development of the Russian pharmaceutical industry. The occasion was a major step toward enhancing global cooperation and increasing Russia's production capacity.

The visit was intended to discuss opportunities for technology transfer and cooperative production of drug substances (DS). The delegation visited BratskChemSyntez's production facilities, which included operational departments and newly constructed facilities that demonstrated the company's strategic potential and dynamic growth.

The alignment of terms and conditions for reaching an agreement on technology transfer and the cooperative production of various drug substances (DS) was the main result of the negotiations. The delegation also visited Pharmasyntez, the parent company, as part of the program, where they examined the solid dosage form production lines. This visit demonstrated the Chinese partners' all-encompassing interest in the Russian drug development process.

The Chinese colleagues noted the Russian production facilities' size, modernity, and rigorous adherence to international GMP standards. The visit confirmed the high level of the Russian pharmaceutical industry and created new avenues for global collaboration.

In order to secure approval and support for this collaborative project with its partners from the People's Republic of China, Pharmasyntez will prepare and submit a plan to the Ministry of Industry and Trade in the near future.

Pharmasyntez started this project to increase the localization of drug substance production in Russia with the goal of advancing the domestic pharmaceutical industry and strengthening the country's position on the global map of pharmaceutical production.